Antipsychotics and borderline personality disorder: Authors' reply
Vollm, Birgit A.
Vollm, Birgit A.
Abstract
Reply by the current authors to the comments made by Jawad Adil (see record 2010-17019-018) on the original article (see record 2010-01466-002). We agree that the conclusions from National Institute for Health and Clinical Excellence (NICE) and our review are surprisingly different, considering similar literature search periods and widely similar inclusion criteria for primary studies. However, our scope was to assess and evaluate 'the mere evidence' of clinical outcomes. The NICE, in contrast, aims at the formulation of instructional recommendations for the British National Health Service. Indeed, there were and still are no Randomized Clinical Trials (RCTs) on quetiapine available. We agree that forest plotting would have contributed to a more immediate understanding of the evidence. However, may we refer you to the full Cochrane review which is to be published soon in the Cochrane Library. Forest plots will be provided there whenever appropriate. Finally, The American Psychiatric Association guidelines recommend low-dose antipsychotics in general, whereas our findings indicate that second-generation antipsychotics are supported by the current RCT evidence in particular. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2010
Type
Commentary
Collections
Citation
Lieb, K., Vollm, B. A. & Stoffers, J. (2010). Antipsychotics and borderline personality disorder: Authors' reply. The British Journal of Psychiatry, 196 (4), pp.332.